ASCO® 2025 Highlights: Presenter Vignette – Kohei Shitara
Kohei Shitara
MD
National Cancer Center Hospital East
LBA4002
Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study.
Interested in learning more about these abstracts and other trials presented at ASCO® 2025? Be sure to register for one of our licensed Best of ASCO® events in a city near you.
This program has been made possible through unrestricted support from Boehringer Ingelheim, Eli Lilly and Ipsen
